摘要(Abstract)：
以蔗糖和谷氨酸为原料,聚乙烯亚胺为钝化剂,合成一种表面带正电荷的、N掺杂的阳离子碳点;通过高分辨透射电子显微镜、傅里叶变换红外光谱、X射线光电子能谱、紫外光谱和荧光光谱等技术手段对制备的阳离子碳点的形貌、表面官能团以及光学特性进行表征;利用荧光光谱考察阳离子碳点对人体纤维原蛋白的猝灭机制;联合同步荧光和圆二色谱,研究阳离子碳点对人体纤维原蛋白空间构象的影响。结果表明:阳离子碳点粒径约为2.2 nm,呈规则圆球形,Zeta电位为+28.7 mV,且表面存在羰基、羧基、羟基和胺基等官能团;在模拟生理条件下,当阳离子碳点浓度为0～2.0μmol/L时,人体纤维原蛋白的荧光随阳离子碳点浓度的增大呈线性静态猝灭,两者以静电作用力结合;阳离子碳点与人体纤维原蛋白的色氨酸残基作用更强,阳离子碳点浓度大于1.0μmol/L时会引起人体纤维原蛋白解螺旋。
关键词(KeyWords)： 阳离子碳点;人体纤维原蛋白;光谱法;相互作用
基金项目(Foundation):国家自然科学基金项目(51802180);; 山西省青年科技研究基金项目(201901D211339);; 山西省“1331工程”重点学科建设计划项目;; 山西省重点学科建设项目
作者(Author): 张慧超,谭奎,葛琳,刘丹,闫丽丽,刘文,乔华,解军
DOI: 10.13349/j.cnki.jdxbn.20200722.001
参考文献(References)：
[1] ZHOU J,ZHOU H,TANG J B,et al.Carbon dots doped with heteroatoms for fluorescent bioimaging:a review[J].Microchimica Acta,2017,184(2):343-368.
[2] 唐志姣,李攻科,胡玉玲.荧光碳点在分析检测中的研究进展[J].分析测试学报,2015,34(8):970-978.
[3] SU Y L,YU T W,CHIANG W H,et al.Hierarchically targeted and penetrated delivery of drugs to tumors by size-changeable graphene quantum dot nanoaircrafts for photolytic therapy[J].Advanced Functional Materials,2017,27(23):1700056.
[4] LIU Z E,XIAO J C,WU X W,et al.Switch-on fluorescent strategy based on N and S co-doped graphene quantum dots (N-S/GQDs) for monitoring pyrophosphate ions in synovial fluid of arthritis patients[J].Sensors and Actuators:B:Chemical,2016,229:217-224.
[5] 樊海,杨海芬,吕俊杰,等.氮磷共掺杂碳点的制备及其在桑色素检测中的应用[J].化学研究与应用,2018,30(4):577-582.
[6] GUO R B,CHEN B,LI F L,et al.Positive carbon dots with dual roles of nanoquencher and reference signal for the ratiometric fluorescence sensing of DNA[J].Sensors and Actuators:B:Chemical,2018,264:193-201.
[7] ZHOU J,DENG W W,WANG Y,et al.Cationic carbon quantum dots derived from alginate for gene delivery:one-step synthesis and cellular uptake[J].Acta Biomaterialia,2016,42:209-219.
[8] DIERENDONCK M,de KOKER S,VERVAET C,et al.Inter-action between polymeric multilayer capsules and immune cells[J].Journal of Controlled Release,2012,161(2):592-599.
[9] PETROS R A,DESIMONE J M.Strategies in the design of nano-particles for therapeutic applications[J].Nature Reviews Drug Discovery,2010,9(8):615-627.
[10] MAITZ M F,SPERLING C,WONGPINYOCHIT T,et al.Biocompatibility assessment of silk nanoparticles:hemocompatibility and internalization by human blood cells[J].Nanomedicine,2017,13(8):2633-2642.
[11] DUGA S,ASSELTA R,SANTAGOSTINO E,et al.Missense mutations in the human β fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion[J].Blood,2000,95(4):1336-1341.
[12] 蔡建周,张武.光谱法研究聚赖氨酸与纤维蛋白原的相互作用[J].光谱学与光谱分析,2017,37(1):166-171.
[13] QIAO H,LI B,ZHANG H C,et al.Effects of the equimolarly mixed cationic-nonionic surfactants of didodecyldimethylammonium bromide and polyoxyethylene sorbitan monooleate 80 on serum proteins:spectroscopic study[J].Journal of Photochemistry and Photobiology,B:Biology,2018,187:151-161.
[14] GONG X J,LU W J,PAAU M C,et al.Facile synthesis of nitrogen-doped carbon dots for Fe3+ sensing and cellular imaging[J].Analytica Chimica Acta,2015,861:74-84.
[15] HU L M,SUN Y,LI S L,et al.Multifunctional carbon dots with high quantum yield for imaging and gene delivery[J].Carbon,2014,67(2):508-513.
[16] VUKI?EVI? M,T?NNESEN H H.Interaction between curcumin and human serum albumin in the presence of excipients and the effect of binding on curcumin photostability[J].Pharmaceutical Development and Technology,2016,21(4):428-436.
[17] ZHAO X N,LIU Y,NIU L Y,et al.Spectroscopic studies on the interaction of bovine serum albumin with surfactants and apigenin[J].Spectrochimica Acta:Part A:Molecular and Biomolecular Spectroscopy,2012,94:357-364.
[18] GUO X J,XU L P,ZHANG L Z,et al.One-pot solid phase pyrolysis synthesis of highly fluorescent nitrogen-doped carbon dots and the interaction with human serum albumin[J].Journal of Luminescence,2018,196:100-110.
[19] MAITY A,PAL U,CHAKRABORTY B,et al.Preferential photochemical interaction of Ru (Ⅲ) doped carbon nano dots with bovine serum albumin over human serum albumin[J].International Journal of Biological Macromolecules,2019,137:483-494.
[20] 乔华,薛燕斌,葛琳,等.高良姜素与牛血清白蛋白作用的光谱研究[J].天然产物研究与开发,2017,29(6):903-908.
